05Oct
05Oct
Siamab Therapeutics and Boehringer Ingelheim Announce Strategic Cancer Immunology Discovery Collaboration to Develop Antibody Therapeutics Targeting Multiple Solid Tumors
Siamab Therapeutics, Inc. and Boehringer Ingelheim announced today that they have entered into a strategic discovery collaboration with the goal of developing anti-cancer therapeutics targeting tumor associated carbohydrate antigens (TACAs). Read more >>
04Oct
New technology helps the blind to see
It's helping the blind to see. A couple in the northern valley was worried that it was an out-of-country scam, but now they want to share what's bringing back a man's sight. Read more >>
04Oct
ESight launches next generation eye wear for visually impaired
The eye wear technology company, eSight, has launched the third generation of its hands-free glasses that provide instant sight and mobility for those with impaired vision. Read more >>
04Oct
Siamab Therapeutics Presents New Data at AACR’s Ovarian Cancer Conference Demonstrating its Anti-STn Antibody Therapeutics Inhibit Tumor Growth in Ovarian Cancer Models
Siamab Therapeutics, Inc., a biopharmaceutical company developing novel cancer immunotherapies, today announced the presentation of new preclinical data for its novel anti-Sialyl-Tn (STn) antibodies and antibody drug conjugates (ADCs) that show inhibition of tumor progression in in vivo and in vitro patient derived xenograft (PDX) ovarian cancer models with complete regression in some treatment arms. Read more >>
01Oct
Applying for Angel Funding- Part 1: An Angel’s Perspective: Hub Angels, Launchpad, Golden Seeds & Boston Harbor Angels give their perspectives
Member David Kessler representing Boston Harbor Angels at this interactive session on Tuesday, October 3! Applying for Angel Funding- Part 1: An Angel’s Perspective. Read more >>
01Oct
Electronic glasses improve sight of legally blind teen
A teen who is legally blind from Bucks County is getting help from electronic glasses that help to improve his sight. Read more >>
30Sep
Commercial breakthrough for fishmeal alternative
KnipBio has received order for several tonnes of its innovative fishmeal alternative, KnipBio Meal (KBM). Read more >>
30Sep
Siamab Therapeutics Presented New Data for its Anti-STn Antibody Therapeutics Showing Myeloid-Derived Suppressor Cells as a Promising Cancer Immunotherapy Target at Cambridge Healthtech Institute’s Targeting Tumor Myeloid Cells Conference
Siamab Therapeutics, Inc., a biopharmaceutical company developing novel cancer immunotherapies, today announced it presented new preclinical data for its novel anti-Sialyl-Tn (STn) antibodies and antibody drug conjugates (ADCs) targeting myeloid-derived suppressor cells (MDSCs) at Cambridge Healthtech Institute’s Inaugural Targeting Tumor Myeloid Cells Conference, held September 27-28, 2017 in Boston. Read more >>
27Sep